Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 3
2004 1
2005 5
2006 7
2007 5
2008 14
2009 12
2010 21
2011 17
2012 13
2013 13
2014 8
2015 9
2016 18
2017 12
2018 13
2019 12
2020 14
2021 12
2022 13
2023 17
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

216 results

Results by year

Filters applied: . Clear all
Page 1
PERCEPTION predicts patient response and resistance to treatment using single-cell transcriptomics of their tumors.
Sinha S, Vegesna R, Mukherjee S, Kammula AV, Dhruba SR, Wu W, Kerr DL, Nair NU, Jones MG, Yosef N, Stroganov OV, Grishagin I, Aldape KD, Blakely CM, Jiang P, Thomas CJ, Benes CH, Bivona TG, Schäffer AA, Ruppin E. Sinha S, et al. Among authors: thomas cj. Nat Cancer. 2024 Apr 18. doi: 10.1038/s43018-024-00756-7. Online ahead of print. Nat Cancer. 2024. PMID: 38637658
Activity of the Ubiquitin-activating Enzyme Inhibitor TAK-243 in Adrenocortical Carcinoma Cell Lines, Patient-derived Organoids, and Murine Xenografts.
Arakawa Y, Jo U, Kumar S, Sun NY, Elloumi F, Thomas A, Roper N, Varghese DG, Takebe N, Zhang X, Ceribelli M, Holland DO, Beck E, Itkin Z, McKnight C, Wilson KM, Travers J, Klumpp-Thomas C, Thomas CJ, Hoang CD, Hernandez JM, Del Rivero J, Pommier Y. Arakawa Y, et al. Among authors: thomas cj. Cancer Res Commun. 2024 Mar 19;4(3):834-848. doi: 10.1158/2767-9764.CRC-24-0085. Cancer Res Commun. 2024. PMID: 38451783 Free PMC article.
High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma.
Arang N, Lubrano S, Ceribelli M, Rigiracciolo DC, Saddawi-Konefka R, Faraji F, Ramirez SI, Kim D, Tosto FA, Stevenson E, Zhou Y, Wang Z, Bogomolovas J, Molinolo AA, Swaney DL, Krogan NJ, Yang J, Coma S, Pachter JA, Aplin AE, Alessi DR, Thomas CJ, Gutkind JS. Arang N, et al. Among authors: thomas cj. Cell Rep Med. 2023 Nov 21;4(11):101244. doi: 10.1016/j.xcrm.2023.101244. Epub 2023 Oct 18. Cell Rep Med. 2023. PMID: 37858338 Free PMC article.
Exploiting the therapeutic vulnerability of IDH-mutant gliomas with zotiraciclib.
Pang Y, Li Q, Sergi Z, Yu G, Sang X, Kim O, Wang H, Ranjan A, Merchant M, Oudit B, Robey RW, Soheilian F, Tran B, Núñez FJ, Zhang M, Song H, Zhang W, Davis D, Gilbert MR, Gottesman MM, Liu Z, Khan J, Thomas CJ, Castro MG, Gujral TS, Wu J. Pang Y, et al. Among authors: thomas cj. bioRxiv [Preprint]. 2024 Jan 2:2023.06.29.547143. doi: 10.1101/2023.06.29.547143. bioRxiv. 2024. PMID: 37786680 Free PMC article. Preprint.
Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma.
Wu JT, Cheuk A, Isanogle K, Robinson C, Zhang X, Ceribelli M, Beck E, Shinn P, Klumpp-Thomas C, Wilson KM, McKnight C, Itkin Z, Sotome H, Hirai H, Calleja E, Wacheck V, Gouker B, Peer CJ, Corvalan N, Milewski D, Kim YY, Figg WD, Edmondson EF, Thomas CJ, Difilippantonio S, Wei JS, Khan J. Wu JT, et al. Among authors: thomas cj. Cancers (Basel). 2023 Aug 9;15(16):4034. doi: 10.3390/cancers15164034. Cancers (Basel). 2023. PMID: 37627061 Free PMC article.
Inhibition of NAD+-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models.
McKay-Corkum GB, Collins VJ, Yeung C, Ito T, Issaq SH, Holland D, Vulikh K, Zhang Y, Lee U, Lei H, Mendoza A, Shern JF, Yohe ME, Yamamoto K, Wilson K, Ji J, Karim BO, Thomas CJ, Krishna MC, Neckers LM, Heske CM. McKay-Corkum GB, et al. Among authors: thomas cj. Clin Cancer Res. 2023 Nov 1;29(21):4479-4491. doi: 10.1158/1078-0432.CCR-23-0200. Clin Cancer Res. 2023. PMID: 37616468
A landscape of response to drug combinations in non-small cell lung cancer.
Nair NU, Greninger P, Zhang X, Friedman AA, Amzallag A, Cortez E, Sahu AD, Lee JS, Dastur A, Egan RK, Murchie E, Ceribelli M, Crowther GS, Beck E, McClanaghan J, Klump-Thomas C, Boisvert JL, Damon LJ, Wilson KM, Ho J, Tam A, McKnight C, Michael S, Itkin Z, Garnett MJ, Engelman JA, Haber DA, Thomas CJ, Ruppin E, Benes CH. Nair NU, et al. Among authors: thomas cj. Nat Commun. 2023 Jun 28;14(1):3830. doi: 10.1038/s41467-023-39528-9. Nat Commun. 2023. PMID: 37380628 Free PMC article.
Drug combinations identified by high-throughput screening promote cell cycle transition and upregulate Smad pathways in myeloma.
Peat TJ, Gaikwad SM, Dubois W, Gyabaah-Kessie N, Zhang S, Gorjifard S, Phyo Z, Andres M, Hughitt VK, Simpson RM, Miller MA, Girvin AT, Taylor A, Williams D, D'Antonio N, Zhang Y, Rajagopalan A, Flietner E, Wilson K, Zhang X, Shinn P, Klumpp-Thomas C, McKnight C, Itkin Z, Chen L, Kazandijian D, Zhang J, Michalowski AM, Simmons JK, Keats J, Thomas CJ, Mock BA. Peat TJ, et al. Among authors: thomas cj. Cancer Lett. 2023 Aug 1;568:216284. doi: 10.1016/j.canlet.2023.216284. Epub 2023 Jun 24. Cancer Lett. 2023. PMID: 37356470
Targeting neddylation sensitizes colorectal cancer to topoisomerase I inhibitors by inactivating the DCAF13-CRL4 ubiquitin ligase complex.
Sun Y, Baechler SA, Zhang X, Kumar S, Factor VM, Arakawa Y, Chau CH, Okamoto K, Parikh A, Walker B, Su YP, Chen J, Ting T, Huang SN, Beck E, Itkin Z, McKnight C, Xie C, Roper N, Nijhawan D, Figg WD, Meltzer PS, Yang JC, Thomas CJ, Pommier Y. Sun Y, et al. Among authors: thomas cj. Nat Commun. 2023 Jun 23;14(1):3762. doi: 10.1038/s41467-023-39374-9. Nat Commun. 2023. PMID: 37353483 Free PMC article.
216 results